SCHEDULE 13G/A: BlackRock Amends Sanofi Stake, Discloses 5.8% Passive Ownership

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.8% passive beneficial ownership stake in Sanofi's common stock as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 9 to its Schedule 13G regarding its beneficial ownership of Sanofi's Common Stock.
• As of March 31, 2025, BlackRock, Inc. beneficially owned an aggregate of 72,127,649 shares of Sanofi common stock.
• This aggregate amount represents 5.8% of Sanofi's common stock outstanding.
• BlackRock, Inc. holds sole voting power over 65,991,886 shares and sole dispositive power over 72,127,649 shares.
• The filing explicitly states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Sanofi.
• Various BlackRock business units, including BlackRock Life Limited, BlackRock Advisors, LLC, and BlackRock Fund Advisors, are involved in the beneficial ownership, with some entities individually owning 5% or greater of the outstanding shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G Amendment) disclosing passive beneficial ownership. It contains factual information without expressing positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• The disclosure of a significant 5.8% stake by a major institutional investor like BlackRock can be interpreted as a vote of confidence in Sanofi's long-term prospects and stability.

Negatives

• NA

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating risks associated with activist investor involvement.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure by a large asset manager, BlackRock, regarding its passive investment in a major global pharmaceutical company, Sanofi. It reflects BlackRock's ongoing portfolio management activities rather than a specific industry trend or competitive action.

Stakeholder Impact

• Shareholders: The continued significant passive ownership by BlackRock may provide a sense of stability and institutional confidence in Sanofi's stock.

Key Dates

Keywords

Sanofi, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Pharmaceuticals, Healthcare